Department of Nutrition, University of North Carolina, Chapel Hill, NC 27599-7461, USA.
Toxicol Appl Pharmacol. 2010 May 15;245(1):47-56. doi: 10.1016/j.taap.2010.01.015. Epub 2010 Feb 4.
Biomethylation is the major pathway for the metabolism of inorganic arsenic (iAs) in many mammalian species, including the human. However, significant interspecies differences have been reported in the rate of in vivo metabolism of iAs and in yields of iAs metabolites found in urine. Liver is considered the primary site for the methylation of iAs and arsenic (+3 oxidation state) methyltransferase (As3mt) is the key enzyme in this pathway. Thus, the As3mt-catalyzed methylation of iAs in the liver determines in part the rate and the pattern of iAs metabolism in various species. We examined kinetics and concentration-response patterns for iAs methylation by cultured primary hepatocytes derived from human, rat, mice, dog, rabbit, and rhesus monkey. Hepatocytes were exposed to [(73)As]arsenite (iAs(III); 0.3, 0.9, 3.0, 9.0 or 30 nmol As/mg protein) for 24 h and radiolabeled metabolites were analyzed in cells and culture media. Hepatocytes from all six species methylated iAs(III) to methylarsenic (MAs) and dimethylarsenic (DMAs). Notably, dog, rat and monkey hepatocytes were considerably more efficient methylators of iAs(III) than mouse, rabbit or human hepatocytes. The low efficiency of mouse, rabbit and human hepatocytes to methylate iAs(III) was associated with inhibition of DMAs production by moderate concentrations of iAs(III) and with retention of iAs and MAs in cells. No significant correlations were found between the rate of iAs methylation and the thioredoxin reductase activity or glutathione concentration, two factors that modulate the activity of recombinant As3mt. No associations between the rates of iAs methylation and As3mt protein structures were found for the six species examined. Immunoblot analyses indicate that the superior arsenic methylation capacities of dog, rat and monkey hepatocytes examined in this study may be associated with a higher As3mt expression. However, factors other than As3mt expression may also contribute to the interspecies differences in the hepatocyte capacity to methylate iAs.
生物甲基化是许多哺乳动物物种(包括人类)中无机砷(iAs)代谢的主要途径。然而,在体内代谢 iAs 的速度以及尿液中发现的 iAs 代谢物的产率方面,不同物种之间存在显著差异。肝脏被认为是 iAs 甲基化的主要部位,砷(+3 氧化态)甲基转移酶(As3mt)是该途径的关键酶。因此,肝脏中 As3mt 催化的 iAs 甲基化在一定程度上决定了不同物种中 iAs 代谢的速度和模式。我们检查了源自人类、大鼠、小鼠、狗、兔和恒河猴的原代肝细胞培养物中 iAs 甲基化的动力学和浓度反应模式。将肝细胞暴露于 [(73)As]亚砷酸盐(iAs(III);0.3、0.9、3.0、9.0 或 30 nmol As/mg 蛋白)24 小时,并在细胞和培养基中分析放射性标记的代谢物。六种物种的肝细胞均将 iAs(III)甲基化为甲基砷(MAs)和二甲基砷(DMAs)。值得注意的是,狗、大鼠和猴子的肝细胞比小鼠、兔子或人类的肝细胞更有效地将 iAs(III)甲基化。小鼠、兔子和人类肝细胞将 iAs(III)甲基化为低效率与适量浓度的 iAs(III)抑制 DMAs 产生以及 iAs 和 MAs 在细胞内的保留有关。在 iAs 甲基化速度与硫氧还蛋白还原酶活性或谷胱甘肽浓度之间未发现显著相关性,这两个因素调节重组 As3mt 的活性。在检查的六个物种中,未发现 iAs 甲基化速度与 As3mt 蛋白结构之间的相关性。免疫印迹分析表明,在本研究中检查的狗、大鼠和猴子肝细胞具有较高的砷甲基化能力,可能与 As3mt 表达较高有关。然而,除了 As3mt 表达之外,其他因素也可能导致肝细胞甲基化 iAs 的能力存在种间差异。